Sarconesin II, a New Antimicrobial Peptide Isolated from Sarconesiopsis magellanica Excretions and Secretions
Antibiotic resistance is at dangerous levels and increasing worldwide. The search for new antimicrobial drugs to counteract this problem is a priority for health institutions and organizations, both globally and in individual countries. Sarconesiopsis magellanica blowfly larval excretions and secret...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2019
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/22630
- Acceso en línea:
- https://doi.org/10.3390/molecules24112077
https://repository.urosario.edu.co/handle/10336/22630
- Palabra clave:
- Antiinfective agent
Antimicrobial cationic peptide
Amino acid sequence
Animal
Bacterium
Biosynthesis
Chemical phenomena
Chemistry
Diptera
Dose response
Drug effect
High performance liquid chromatography
Isolation and purification
Mass spectrometry
Metabolism
Microbial sensitivity test
Molecular model
Protein conformation
Structure activity relation
Amino acid sequence
Animals
Anti-bacterial agents
Antimicrobial cationic peptides
Bacteria
Chemical phenomena
Diptera
Mass spectrometry
Microbial sensitivity tests
Protein conformation
Structure-activity relationship
Alpha-helix
Antimicrobial peptide
Calliphoridae
Drug
Sarconesiopsis magellanica
drug
molecular
high pressure liquid
Chromatography
Dose-response relationship
Models
- Rights
- License
- Abierto (Texto Completo)
Summary: | Antibiotic resistance is at dangerous levels and increasing worldwide. The search for new antimicrobial drugs to counteract this problem is a priority for health institutions and organizations, both globally and in individual countries. Sarconesiopsis magellanica blowfly larval excretions and secretions (ES) are an important source for isolating antimicrobial peptides (AMPs). This study aims to identify and characterize a new S. magellanica AMP. RP-HPLC was used to fractionate ES, using C18 columns, and their antimicrobial activity was evaluated. The peptide sequence of the fraction collected at 43.7 min was determined by mass spectrometry (MS). Fluorescence and electronic microscopy were used to evaluate the mechanism of action. Toxicity was tested on HeLa cells and human erythrocytes; physicochemical properties were evaluated. The molecule in the ES was characterized as sarconesin II and it showed activity against Gram-negative (Escherichia coli MG1655, Pseudomonas aeruginosa ATCC 27853, P. aeruginosa PA14) and Gram-positive (Staphylococcus aureus ATCC 29213, Micrococcus luteus A270) bacteria. The lowest minimum inhibitory concentration obtained was 1.9 µM for M. luteus A270; the AMP had no toxicity in any cells tested here and its action in bacterial membrane and DNA was confirmed. Sarconesin II was documented as a conserved domain of the ATP synthase protein belonging to the Fli-1 superfamily. The data reported here indicated that peptides could be alternative therapeutic candidates for use in infections against Gram-negative and Gram-positive bacteria and eventually as a new resource of compounds for combating multidrug-resistant bacteria. © 2019 by the authors. |
---|